Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Correction: The multiple sclerosis rating scale, revised (MSRS-R): development, refinement, and psychometric validation using an online community.
Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program.
Progressive Disorganization of Paranodal Junctions and Compact Myelin Due to Loss of DCC Expression by Oligodendrocytes.
Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study.
Deep-brain stimulation for Parkinson's disease.
VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials
Discovery of A-971432, an Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonists for the Potential Treatment of Neurodegenerative Disorders.
Application of laser radiation and magnetostimulation in therapy of patients with multiple sclerosis.
The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.
Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Estrogen receptor (ER) β expression in oligodendrocytes is required for attenuation of clinical disease by an ERβ ligand.
Mortality and Cause of Death in Multiple Sclerosis: Findings from a Prospective Population-Based Cohort in Bizkaia, Basque Country, Spain.
Myelin Basic Protein and a Multiple Sclerosis-related MBP-peptide Bind to Oligonucleotides.
Outcomes after Percutaneous Surgery for Patients with Multiple Sclerosis Related Trigeminal Neuralgia.
Magnetic resonance imaging signatures of vascular pathology in multiple sclerosis.
Myelin-derived lipids modulate macrophage activity by liver x receptor activation.
[Understanding needs of people with Multiple Sclerosis. Perspective of patients and significant others in the German-speaking part of Switzerland].
Severe relapses under fingolimod treatment prescribed after natalizumab.
Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.
Characterization of the interaction between astrocytes and encephalitogenic lymphocytes during the development of experimental autoimmune encephalitomyelitis (EAE) in mice.
Endovascular Treatment of Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: A retrospective study.
Early onset optic neuritis following measles-rubella vaccination.
Residential Distance to High-voltage Power Lines and Risk of Neurodegenerative Diseases: a Danish Population-based Case-Control Study.
Defining Encephalopathy in Acute Disseminated Encephalomyelitis.
Pages
« first
‹ previous
…
316
317
318
319
320
321
322
323
324
…
next ›
last »